Dynavax is a commercial-stage biopharmaceutical company built on the foundation of our significant experience and expertise in vaccine development and ...
People also ask
Is Dvax a buy sell or hold?
Who are DVAX competitors?
Where is Dynavax located?
What vaccines does Dynavax make?
Dynavax Technologies is focused on leveraging the power of the body's innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.
Feb 22, 2024 · Total revenues for the fourth quarter of 2023 were $55.6 million, compared to $184.5 million for the fourth quarter of 2022, and $232.3 million ...
Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the Earnings Calendar to see dates for ...
Nov 3, 2023 · I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin ...
Find the latest institutional holdings data for Dynavax Technologies Corporation Common Stock (DVAX) including shareholders, ownership summaries, ...
Feb 23, 2023 · Share this article · Total revenue for the fourth quarter of 2022 was $184.5 million, compared to $195.1 million for the fourth quarter of 2021.